Indian pharma: lofty aims in the midst of chaos

Akshara· Host0:00

[upbeat music] In today's episode, we'll break down two important stories. First, we'll talk about Indian pharma having lofty aims in the midst of chaos, and then we'll talk about India's credit card industry splitting in two. Welcome back to The Daily Brief by Zerodha, where we cut through the noise to help you understand what's actually happening in the most important stories from business and markets. I'm your host Akshara, and today is Wednesday, 27th May. Coming to the first story, Indian pharma is going through a period of rapid change. Yes, US tariffs and geopolitical uncertainty are forcing companies to rethink their geographical mix. But relievingly, the Indian market itself has become the fastest-growing engine for most players. Indian firms are also ferociously working on expanding to other developing markets. Meanwhile, Indian pharma is in the midst of a generational shift toward chronic therapies like cardiac, respiratory, diabetes, and oncology. One chronic solution in particular, GLP-1, promises to be a gold rush, and two of the biggest acquisitions in the sector's history landed within six weeks of each other. Clearly, there's a lot to unpack this quarter. So we looked at the Q4 FY26 earnings calls of four of India's largest pharma companies: Sun Pharma, Torrent Pharmaceuticals, Zydus Lifesciences, and Cipla. All of these companies have points of agreements and divergence on what they think Indian pharma will look like over the next decade. Of course, the numbers matter. So Sun